S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
All the trading advice you’ve ever received boils down to this (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
All the trading advice you’ve ever received boils down to this (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
All the trading advice you’ve ever received boils down to this (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
All the trading advice you’ve ever received boils down to this (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
All the trading advice you’ve ever received boils down to this (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
All the trading advice you’ve ever received boils down to this (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
All the trading advice you’ve ever received boils down to this (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
All the trading advice you’ve ever received boils down to this (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs

BioNTech Stock Price, News & Analysis (NASDAQ:BNTX)

$99.40
-1.01 (-1.01%)
(As of 12/1/2023 ET)
Compare
Today's Range
$94.70
▼
$99.64
50-Day Range
$90.91
▼
$112.75
52-Week Range
$88.00
▼
$188.99
Volume
802,521 shs
Average Volume
682,438 shs
Market Capitalization
$23.63 billion
P/E Ratio
8.62
Dividend Yield
N/A
Price Target
$151.46
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

BioNTech MarketRank™ Stock Analysis

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
52.4% Upside
$151.46 Price Target
Short Interest
Healthy
1.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.02mentions of BioNTech in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-54.05%
From $4.81 to $2.21 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

362nd out of 954 stocks

Biological Products, Except Diagnostic Industry

61st out of 159 stocks

See Top Rated MarketRank™ Stocks Here

BNTX stock logo

About BioNTech Stock (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BNTX Stock Price History

BNTX Stock News Headlines

December 1, 2023 | msn.com
BioNTech Stock Downgraded, Analyst Reflects Concerns Over Growth and Pipeline Development
December 1, 2023 | msn.com
BioNTech downgraded at JPMorgan on COVID-related headwinds
December 2, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
December 1, 2023 | finance.yahoo.com
BioNTech ADRs drop after JPMorgan lowers outlook to "underweight"
December 1, 2023 | markets.businessinsider.com
6 Analysts Have This to Say About BioNTech
November 29, 2023 | americanbankingnews.com
BioNTech (NASDAQ:BNTX) Rating Reiterated by HC Wainwright
November 28, 2023 | realmoney.thestreet.com
BioNTech price target lowered to $110 from $153 at UBS
November 21, 2023 | bizjournals.com
European patent office declares Moderna's Covid vaccine patent invalid
December 2, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
November 7, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), BioNTech SE (BNTX) and Sensei Biotherapeutics (SNSE)
November 7, 2023 | markets.businessinsider.com
BionTech SE’s Adjusted Forecast and Future Projections: An Analysis of the Hold Rating Decision
November 7, 2023 | msn.com
BioNTech (NASDAQ:BNTX) Rises After Q3 Numbers
November 6, 2023 | markets.businessinsider.com
Crude Oil Moves Higher; BioNTech Lowers 2023 Sales Outlook
November 6, 2023 | markets.businessinsider.com
BioNTech Q3 Profit Falls, Trims FY23 Vaccine Revenue Outlook
November 6, 2023 | msn.com
Like Moderna, BioNTech Cuts Annual Sales Forecast By 20% As Pandemic Fades
November 6, 2023 | msn.com
BioNTech Stock Surges On Surprise Profit, Strong Sales. But Drugmaker Cuts Outlook.
November 6, 2023 | realmoney.thestreet.com
BioNTech Gets a Shot in the Arm After Earnings: Is It Sustainable?
November 6, 2023 | seekingalpha.com
BioNTech Q3 Earnings Review: COVID Revenues Downgrade Makes Prognosis Gloomy
November 6, 2023 | markets.businessinsider.com
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
November 6, 2023 | finance.yahoo.com
BioNTech Stock Jumps On Surprise Profit, Sales Beat
November 6, 2023 | seekingalpha.com
BioNTech SE 2023 Q3 - Results - Earnings Call Presentation
November 2, 2023 | markets.businessinsider.com
BioNTech Receives Buy Rating Amid Anticipated Revenue Increase and Comirnaty Booster Approval
October 31, 2023 | morningstar.com
BioNTech SE ADR BNTX
October 27, 2023 | markets.businessinsider.com
Positive Phase 1/2 Study Results and Steady Revenue Prospects Boost BioNTech SE’s Buy Rating
October 26, 2023 | investing.com
Pfizer, BioNtech say flu-COVID shot generates strong immune response in trial
October 23, 2023 | benzinga.com
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
October 23, 2023 | finance.yahoo.com
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/25/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNTX
CUSIP
N/A
CIK
1776985
Web
www.biontech.de
Phone
49-61-31908-40
Fax
49-6131-908-4390
Employees
4,530
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$151.46
High Stock Price Target
$260.00
Low Stock Price Target
$99.00
Potential Upside/Downside
+52.4%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$11.53
Trailing P/E Ratio
8.62
Forward P/E Ratio
20.67
P/E Growth
N/A
Net Income
$9.94 billion
Net Margins
41.09%
Pretax Margin
52.86%
Return on Equity
13.15%
Return on Assets
11.73%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
10.38
Quick Ratio
10.14

Sales & Book Value

Annual Sales
$18.24 billion
Price / Sales
1.30
Cash Flow
$41.59 per share
Price / Cash Flow
2.39
Book Value
$90.96 per share
Price / Book
1.09

Miscellaneous

Outstanding Shares
237,710,000
Free Float
192,074,000
Market Cap
$23.63 billion
Optionable
Not Optionable
Beta
0.28

Social Links

12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Prof. Ugur Sahin M.D. (Age 58)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $446k
  • Dr. Ozlem Tureci M.D. (Age 56)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $829k
  • Mr. Jens H. Holstein (Age 60)
    CFO & Member of Management Board
    Comp: $873k
  • Dr. Sierk Poetting Ph.D. (Age 50)
    MD, COO & Member of Management Board
    Comp: $917k
  • Mr. Ryan Richardson (Age 44)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $443k
  • Mr. Sean Marett (Age 58)
    Chief Business Officer, Chief Commercial Officer & Member of Management Board
    Comp: $850k
  • Dr. James Timothy Patrick Ryan Ph.D. (Age 48)
    Chief Legal Officer & Member of the Management Board
  • Sylke Maas Ph.D.
    Vice President of Investor Relations and Business Strategy
  • Michael Boehler
    MD & Head of Global External Communications
  • Dr. Oliver Hennig Ph.D.
    Senior Vice President of Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of BioNTech was last updated on Tuesday, November 28, 2023 at 9:32 PM.

Pros

Here are some ways that investors could benefit from investing in BioNTech SE:

  • BioNTech SE is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. This positions the company in a high-growth industry with significant potential for innovation and revenue growth.
  • The company has a robust pipeline of product candidates in various stages of clinical trials. These include BNT111, BNT112, BNT113, BNT115, and BNT116, which are being tested for the treatment of advanced melanoma, prostate cancer, HPV 16+ head and neck cancers, ovarian cancer, and non-small cell lung cancer, respectively. These product candidates represent potential breakthroughs in cancer treatment and could generate substantial returns if successful.
  • BioNTech SE has established collaborations with reputable pharmaceutical companies such as Genentech, Sanofi, Pfizer, and Genmab. These collaborations provide access to resources, expertise, and potential commercialization opportunities, which can enhance the company's chances of success and market penetration.
  • The company is actively developing a prophylactic vaccine for various infectious diseases, including shingles, malaria, tuberculosis, and HSV-2. The global demand for vaccines has increased significantly due to the COVID-19 pandemic, and BioNTech SE's expertise in vaccine development positions it well to capitalize on this growing market.
  • The current stock price of BioNTech SE (symbol: BNTX) reflects the market's positive sentiment towards the company's prospects. Investors who believe in the company's growth potential may see an opportunity for capital appreciation.

Cons

Investors should be bearish about investing in BioNTech SE for these reasons:

  • The biotechnology industry is highly competitive and subject to regulatory uncertainties. The success of BioNTech SE's product candidates is not guaranteed, and any setbacks in clinical trials or regulatory approvals could negatively impact the company's financial performance.
  • The company's financials may be volatile due to the nature of its business. Biotechnology companies often experience fluctuations in revenue and profitability as they progress through different stages of drug development and commercialization.
  • Investing in clinical-stage biotechnology companies carries inherent risks. The outcomes of clinical trials are uncertain, and there is a possibility of adverse events or safety concerns arising during the testing of product candidates.
  • The success of BioNTech SE's product candidates depends on factors such as market acceptance, pricing, reimbursement, and competition. These factors can be unpredictable and may impact the commercial viability of the company's products.
  • Investors should carefully consider their risk tolerance and investment objectives before investing in BioNTech SE. The biotechnology sector can be volatile, and individual stock performance may deviate from broader market trends.














BNTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings or view top-rated stocks.

What is BioNTech's stock price target for 2024?

10 equities research analysts have issued 12 month price objectives for BioNTech's stock. Their BNTX share price targets range from $99.00 to $260.00. On average, they predict the company's share price to reach $151.46 in the next year. This suggests a possible upside of 52.4% from the stock's current price.
View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2023?

BioNTech's stock was trading at $150.22 at the start of the year. Since then, BNTX shares have decreased by 33.8% and is now trading at $99.40.
View the best growth stocks for 2023 here.

Are investors shorting BioNTech?

BioNTech saw a decline in short interest in November. As of November 15th, there was short interest totaling 2,660,000 shares, a decline of 18.4% from the October 31st total of 3,260,000 shares. Based on an average daily volume of 636,800 shares, the days-to-cover ratio is currently 4.2 days. Currently, 1.1% of the shares of the stock are sold short.
View BioNTech's Short Interest.

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our BNTX earnings forecast.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) issued its earnings results on Monday, November, 6th. The company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $1.26. The business earned $895.30 million during the quarter, compared to analysts' expectations of $850.50 million. BioNTech had a trailing twelve-month return on equity of 13.15% and a net margin of 41.09%. The business's revenue for the quarter was down 74.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $7.04 EPS.

What ETFs hold BioNTech's stock?

ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and iShares Biotechnology ETF (IBB).

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

(BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Who are BioNTech's major shareholders?

BioNTech's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.59%), Primecap Management Co. CA (1.93%), Flossbach Von Storch AG (1.47%), Artisan Partners Limited Partnership (0.31%), Altrinsic Global Advisors LLC (0.29%) and Morgan Stanley (0.24%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
This page (NASDAQ:BNTX) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -